Abstract
Pharmacogenomics aims to unravel the way that human genetic variation affects drug efficacy and toxicity. Genome-wide association studies and candidate gene findings suggest that genetic approaches may help choose the most appropriate drug and dosage while preventing adverse drug reactions (ADRs). Pain is an unpleasant feeling that usually results from tissue damage. The management of different types of pain (acute, chronic, inflammatory, neuropathic, or cancer) is challenging. Currently, drug intervention is the first-line therapy for resolving pain. However, differences in drug efficacy between individuals are common with pain medications. Moreover, some patients experience ADRs after being treated with specific pain drugs. This review discusses the use of drugs for pain management in the context of the recent pharmacogenomic studies on ADRs and drug efficacy.
| Original language | English |
|---|---|
| Pages (from-to) | 24-30 |
| Number of pages | 7 |
| Journal | Acta Anaesthesiologica Taiwanica |
| Volume | 54 |
| Issue number | 1 |
| DOIs | |
| State | Published - 1 Mar 2016 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- adverse drug reactions
- genome wide association studies
- personalized medicine
- pharmacogenomics
Fingerprint
Dive into the research topics of 'Pharmacogenomics for personalized pain medicine'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver